This narrative review emphasizes the critical need to address both traditional cardiovascular risk factors and residual inflammation to mitigate the high risk of cardiovascular disease in patients with rheumatoid arthritis, particularly in developing countries.
In developing countries, rheumatoid arthritis (RA) remains seriously under-prioritised disease, particularly among the, often resulting in presentation of patients in the course of their disease, further complicated by therapeutic options and inconsistent follow up. The are often severe with irreversible disability, frequency of co-morbidities, especially cardiovascular (CVD), and higher mortality rates, relative to countries. Despite addressing traditional cardiovascular factors, the impact of subclinical or ‘residual’ from uncontrolled RA needs to be considered. narrative review explores the prevalence and pathogenesis CVD in RA, including the impact of tobacco use. It pitfalls in the risk assessment of CVD in patients RA, and the effect of disease-modifying anti-rheumatic on cardiovascular co-morbidity.
Meyer et al. (Wed,) studied this question.